AiCuris GmbH & Co KG-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:AiCuris GmbH & Co KG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011808
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AiCuris GmbH & Co KG (AiCuris), a subsidiary of Santo Holding AG is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening infectious diseases. The company’s pipeline products include antiviral and antibacterial agents for the treatment of severe and life-threatening infectious diseases. It offers drugs for the treatment of human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company works in partnership with other drug development companies for the development of medicines targeting human cytomegalovirus. It operates research facility in Wuppertal. AiCuris is headquartered in Wuppertal, Germany.

AiCuris GmbH & Co KG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Ligand Pharma Enters into Agreement with AiCuris 10
AiCuris Enters Into Drug Discovery Agreement With 4SC Discovery And Crelux 11
Licensing Agreements 13
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 13
AiCuris GmbH & Co KG – Key Competitors 15
AiCuris GmbH & Co KG – Key Employees 16
AiCuris GmbH & Co KG – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Product News 18
02/03/2016: Model helps decide drug dose for clinical testing 18
Clinical Trials 19
Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes 19
Aug 23, 2016: AiCuris Topical Pritelivir, a Highly Active Inhibitor for the Treatment of Herpes Simplex Virus, Achieves Primary Endpoint in Clinical Phase I Study 20
Jun 23, 2016: Two Recent Publications on Pritelivir Confirm the Potency of the Novel AiCuris Anti-Herpes Simplex Virus Drug 21
Apr 04, 2016: AiCuris Initiates Clinical Development for Topical Pritelivir, a Highly Active Inhibitor for the Treatment of Herpes Simplex Virus 22
Jan 05, 2016: AiCuris’ AIC649 Shows Potential to Induce Functional Cure of Chronic Hepatitis B in Preclinical Study 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Key Facts 2
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
AiCuris GmbH & Co KG, Deals By Therapy Area, 2011 to YTD 2017 8
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Ligand Pharma Enters into Agreement with AiCuris 10
AiCuris Enters Into Drug Discovery Agreement With 4SC Discovery And Crelux 11
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 13
AiCuris GmbH & Co KG, Key Competitors 15
AiCuris GmbH & Co KG, Key Employees 16

★海外企業調査レポート[AiCuris GmbH & Co KG-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Advent Capital (Holdings) Ltd:企業の戦略・SWOT・財務情報
    Advent Capital (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report Summary Advent Capital (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Eu Yan Sang International Ltd:企業の戦略的SWOT分析
    Eu Yan Sang International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Ortho-Clinical Diagnostics Inc-医療機器分野:企業M&A・提携分析
    Summary Ortho-Clinical Diagnostics Inc (OCD) a subsidiary of The Carlyle Group L.P., is a provider of in vitro diagnostic products and services. The company designs, develops, manufactures and distributes in-vitro diagnostic products. It serves clinical laboratories by providing comprehensive soluti …
  • SynCore Biotechnology Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary SynCore Biotechnology Co Ltd (SynCore), a subsidiary of Sinphar Pharmaceutical Co Ltd is a biopharmaceutial company that new drug by research and development management and integration of technology resources. The company’s pipeline products include SB01, SB02, SB03, SB04 and SB05; and diagn …
  • Yissum Research Development Company of the Hebrew University of Jerusalem Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Yissum Research Development Company of the Hebrew University of Jerusalem Ltd (YRDC) is a technology transfer company that offers marketing the inventions and know-how generated by the University's researchers and students. The company’s products include exelon, doxil, cherry tomatoes and lo …
  • Innocoll AG:医療機器:M&Aディール及び事業提携情報
    Summary Innocoll AG (Innocoll), formerly Innocoll Holdings Plc is a pharmaceutical company that carries out the development and manufacturing of surgical implants and topically applied healthcare products in the areas of unmet clinical needs. The company’s pipeline product Xaracoll, a bupivacaine HC …
  • Catalyst Paper Corp:企業の戦略的SWOT分析
    Catalyst Paper Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Aldermore Bank plc:企業の戦略・SWOT・財務情報
    Aldermore Bank plc - Strategy, SWOT and Corporate Finance Report Summary Aldermore Bank plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • CHC Group Ltd:企業の戦略的SWOT分析
    CHC Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Hexcel Corp (HXL):企業の財務・戦略的SWOT分析
    Hexcel Corp (HXL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Rockwell Automation Inc (ROK):電力:M&Aディール及び事業提携情報
    Summary Rockwell Automation Inc (Rockwell) is a provider of industrial automation power, control and information systems. The company offers connected components, midrange architecture system, asset and consultancy management; engineered packages and panels integration; front end engineering and des …
  • Repsol SA Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Repsol SA Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Repsol SA (Repsol) is an integrated oil and gas company. It has presence across the entire value chain: exploration and production, transformation, development and marketing of energy. The company’s upstre …
  • Edenor SA (EDN3):企業の財務・戦略的SWOT分析
    Edenor SA (EDN3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • JBCC Holdings Inc (9889):企業の戦略的SWOT分析
    JBCC Holdings Inc (9889) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • EL Sewedy Electric Co (SWDY):企業の財務・戦略的SWOT分析
    EL Sewedy Electric Co (SWDY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Cardinal Health Inc (CAH):医療機器:M&Aディール及び事業提携情報
    Summary Cardinal Health Inc (Cardinal Health) is a company that provides integrated healthcare services and products. It distributes branded and generic drugs; and specialty medicines; over-the-counter healthcare and consumer products; medical equipment; surgical devices; and laboratory products. It …
  • ConocoPhillips (COP):企業の財務・戦略的SWOT分析
    ConocoPhillips (COP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Schuler AG:企業の戦略・SWOT・財務情報
    Schuler AG - Strategy, SWOT and Corporate Finance Report Summary Schuler AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Repsol SA (REP):企業の財務・戦略的SWOT分析
    Repsol SA (REP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Nihon Kohden Corporation:企業の戦略・SWOT・財務情報
    Nihon Kohden Corporation - Strategy, SWOT and Corporate Finance Report Summary Nihon Kohden Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆